Location History:
- Leinfelden-Echterdingen, DE (2015)
- Kist, GB (2018)
Company Filing History:
Years Active: 2015-2018
Title: Innovations of Harald Wajant in Antibody-Cytokine Fusion Proteins
Introduction
Harald Wajant is a notable inventor based in Kist, GB, recognized for his contributions to the field of biotechnology. He has been instrumental in developing innovative therapeutic agents that leverage the power of antibody-cytokine fusion proteins. With a total of 2 patents, Wajant's work focuses on enhancing the efficacy of treatments for various diseases, particularly in targeting tumor tissues.
Latest Patents
Wajant's latest patents include the invention of site-specific antibody-mediated activation of proapoptotic cytokines, known as AMAIZE. This invention involves antibody-cytokine fusion proteins that possess proapoptotic and immune-modulating properties. The cytokine moiety in these proteins has a bioactivity that is initially very low or restricted to specific receptor subtypes. The full biological activity of these reagents is realized only after the antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By carefully selecting the antibody specificity, the cytokine activity can be directed to the tissue that requires treatment, such as tumor tissue. This approach allows for the production of therapeutic agents that are specifically designed and optimized for particular indications or tumor entities.
Career Highlights
Wajant is currently associated with BioNTech AG, a leading biotechnology company known for its innovative approaches to cancer treatment and vaccine development. His work at BioNTech AG has significantly contributed to the advancement of therapeutic strategies in immunotherapy.
Collaborations
Throughout his career, Wajant has collaborated with esteemed colleagues, including Klaus Pfizenmaier and Dieter Moosmayer. These collaborations have fostered a rich environment for innovation and have led to significant advancements in the field of antibody-mediated therapies.
Conclusion
Harald Wajant's contributions to the development of antibody-cytokine fusion proteins represent a significant advancement in targeted therapies for cancer treatment. His innovative approach continues to pave the way for new therapeutic options that can improve patient outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.